Ponatinib is a benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABLT315I. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a member of benzamides, a N-methylpiperazine, an imidazopyridazine, an acetylenic compound and a member of (trifluoromethyl)benzenes. It is a conjugate base of a ponatinib(1+).
